Adicet Bio enters into ATM equity offering agreement with Jefferies LLC

Adicet Bio, Inc.

Agreement allows sale of common stock from time to time through Jefferies as agent or principal.
Jefferies to receive 3.0% of gross proceeds from shares sold under the ATM program.
Shares will be issued under existing shelf registration statement (S-3) and a prospectus supplement filed March 22, 2024.
Either party may terminate the agreement at any time upon written notice; no minimum sale obligation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Adicet Bio, Inc. entered into Sales Agreement with Jefferies LLC valued at 3.0% of the gross proceeds (effective 2024-03-22).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: 3.0% of the gross proceeds
Effective: 2024-03-22

Exact text from the filing

On March 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Open Market Sales Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent or principal.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-035366

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.